| molecular function |
|---|
| | GO:0008047 | | enzyme activator activity | | Binds to and increases the activity of an enzyme. |
| | GO:0055102 | | lipase inhibitor activity | | Stops, prevents or reduces the activity of a lipase, an enzyme that catalyzes of the hydrolysis of a lipid. |
| | GO:0008289 | | lipid binding | | Interacting selectively and non-covalently with a lipid. |
| | GO:0060230 | | lipoprotein lipase activator activity | | Binds to and increases the activity of a lipoprotein lipase, an enzyme that catalyzes of the hydrolysis of a lipid within a lipoprotein. |
| | GO:0016004 | | phospholipase activator activity | | Increases the activity of a phospholipase, an enzyme that catalyzes of the hydrolysis of a glycerophospholipid. |
| | GO:0043274 | | phospholipase binding | | Interacting selectively and non-covalently with any phospholipase, enzymes that catalyze of the hydrolysis of a glycerophospholipid. |
| | GO:0042803 | | protein homodimerization activity | | Interacting selectively and non-covalently with an identical protein to form a homodimer. |
| biological process |
|---|
| | GO:0033344 | | cholesterol efflux | | The directed movement of cholesterol, cholest-5-en-3-beta-ol, out of a cell or organelle. |
| | GO:0042632 | | cholesterol homeostasis | | Any process involved in the maintenance of an internal steady state of cholesterol within an organism or cell. |
| | GO:0034382 | | chylomicron remnant clearance | | The process in which a chylomicron remnant is removed from the blood via receptor-mediated endocytosis into liver cells and its constituent parts degraded. |
| | GO:0034371 | | chylomicron remodeling | | The acquisition, loss or modification of a protein or lipid within a chylomicron, including the hydrolysis of triglyceride by lipoprotein lipase and the subsequent loss of free fatty acid. |
| | GO:0034384 | | high-density lipoprotein particle clearance | | The process in which a high-density lipoprotein particle is removed from the blood via receptor-mediated endocytosis and its constituent parts degraded. |
| | GO:0016042 | | lipid catabolic process | | The chemical reactions and pathways resulting in the breakdown of lipids, compounds soluble in an organic solvent but not, or sparingly, in an aqueous solvent. |
| | GO:0006629 | | lipid metabolic process | | The chemical reactions and pathways involving lipids, compounds soluble in an organic solvent but not, or sparingly, in an aqueous solvent. Includes fatty acids; neutral fats, other fatty-acid esters, and soaps; long-chain (fatty) alcohols and waxes; sphingoids and other long-chain bases; glycolipids, phospholipids and sphingolipids; and carotenes, polyprenols, sterols, terpenes and other isoprenoids. |
| | GO:0006869 | | lipid transport | | The directed movement of lipids into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore. Lipids are compounds soluble in an organic solvent but not, or sparingly, in an aqueous solvent. |
| | GO:0042157 | | lipoprotein metabolic process | | The chemical reactions and pathways involving any conjugated, water-soluble protein in which the covalently attached nonprotein group consists of a lipid or lipids. |
| | GO:0043086 | | negative regulation of catalytic activity | | Any process that stops or reduces the activity of an enzyme. |
| | GO:0032375 | | negative regulation of cholesterol transport | | Any process that stops, prevents, or reduces the frequency, rate or extent of the directed movement of cholesterol into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore. |
| | GO:0045833 | | negative regulation of lipid metabolic process | | Any process that stops, prevents, or reduces the frequency, rate or extent of the chemical reactions and pathways involving lipids. |
| | GO:0048261 | | negative regulation of receptor-mediated endocytosis | | Any process that stops, prevents, or reduces the frequency, rate or extent of receptor mediated endocytosis, the uptake of external materials by cells, utilizing receptors to ensure specificity of transport. |
| | GO:0010916 | | negative regulation of very-low-density lipoprotein particle clearance | | Any process that decreases the rate, frequency or extent of very-low-density lipoprotein particle clearance. Very-low-density lipoprotein particle clearance is the process in which a very-low-density lipoprotein particle is removed from the blood via receptor-mediated endocytosis and its constituent parts degraded. |
| | GO:0033700 | | phospholipid efflux | | The directed movement of a phospholipid out of a cell or organelle. |
| | GO:0045723 | | positive regulation of fatty acid biosynthetic process | | Any process that activates or increases the frequency, rate or extent of the chemical reactions and pathways resulting in the formation of fatty acids. |
| | GO:0051006 | | positive regulation of lipoprotein lipase activity | | Any process that activates or increases the activity of the enzyme lipoprotein lipase. |
| | GO:0010518 | | positive regulation of phospholipase activity | | Any process that increases the frequency, rate or extent of phospholipase activity, the hydrolysis of a phospholipid. |
| | GO:0060697 | | positive regulation of phospholipid catabolic process | | Any process that increases the rate, frequency, or extent of phospholipid catabolism, the chemical reactions and pathways resulting in the breakdown of phospholipids, any lipid containing phosphoric acid as a mono- or diester. |
| | GO:0010898 | | positive regulation of triglyceride catabolic process | | Any process that increases the frequency, rate, or extent of the chemical reactions and pathways resulting in the breakdown of triglyceride. |
| | GO:0010902 | | positive regulation of very-low-density lipoprotein particle remodeling | | Any process that increases the rate, frequency or extent of very-low-density lipoprotein particle remodeling. Very-low-density lipoprotein particle remodeling is the acquisition, loss or modification of a protein or lipid within a very-low-density lipoprotein particle, including the hydrolysis of triglyceride by hepatic lipase or lipoprotein lipase and the subsequent loss of free fatty acid. |
| | GO:0001523 | | retinoid metabolic process | | The chemical reactions and pathways involving retinoids, any member of a class of isoprenoids that contain or are derived from four prenyl groups linked head-to-tail. Retinoids include retinol and retinal and structurally similar natural derivatives or synthetic compounds, but need not have vitamin A activity. |
| | GO:0043691 | | reverse cholesterol transport | | The directed movement of peripheral cell cholesterol, cholest-5-en-3-beta-ol, towards the liver for catabolism. |
| | GO:0006810 | | transport | | The directed movement of substances (such as macromolecules, small molecules, ions) or cellular components (such as complexes and organelles) into, out of or within a cell, or between cells, or within a multicellular organism by means of some agent such as a transporter, pore or motor protein. |
| | GO:0070328 | | triglyceride homeostasis | | Any process involved in the maintenance of an internal steady state of triglyceride within an organism or cell. |
| | GO:0034370 | | triglyceride-rich lipoprotein particle remodeling | | The acquisition, loss or modification of a protein or lipid within a triglyceride-rich lipoprotein particle, including the hydrolysis of triglyceride by lipoprotein lipase, with the subsequent loss of free fatty acid, and the transfer of cholesterol esters to a triglyceride-rich lipoprotein particle by cholesteryl ester transfer protein (CETP), with the simultaneous transfer of triglyceride from a triglyceride-rich lipoprotein particle. |
| | GO:0034372 | | very-low-density lipoprotein particle remodeling | | The acquisition, loss or modification of a protein or lipid within a very-low-density lipoprotein particle, including the hydrolysis of triglyceride by hepatic lipase or lipoprotein lipase and the subsequent loss of free fatty acid. |
| cellular component |
|---|
| | GO:0042627 | | chylomicron | | A large lipoprotein particle (diameter 75-1200 nm) composed of a central core of triglycerides and cholesterol surrounded by a protein-phospholipid coating. The proteins include one molecule of apolipoprotein B-48 and may include a variety of apolipoproteins, including APOAs, APOCs and APOE. Chylomicrons are found in blood or lymph and carry lipids from the intestines into other body tissues. |
| | GO:0005769 | | early endosome | | A membrane-bounded organelle that receives incoming material from primary endocytic vesicles that have been generated by clathrin-dependent and clathrin-independent endocytosis; vesicles fuse with the early endosome to deliver cargo for sorting into recycling or degradation pathways. |
| | GO:0070062 | | extracellular exosome | | A vesicle that is released into the extracellular region by fusion of the limiting endosomal membrane of a multivesicular body with the plasma membrane. Extracellular exosomes, also simply called exosomes, have a diameter of about 40-100 nm. |
| | GO:0005576 | | extracellular region | | The space external to the outermost structure of a cell. For cells without external protective or external encapsulating structures this refers to space outside of the plasma membrane. This term covers the host cell environment outside an intracellular parasite. |
| | GO:0005615 | | extracellular space | | That part of a multicellular organism outside the cells proper, usually taken to be outside the plasma membranes, and occupied by fluid. |
| | GO:0034364 | | high-density lipoprotein particle | | A lipoprotein particle with a high density (typically 1.063-1.21 g/ml) and a diameter of 5-10 nm that contains APOAs and may contain APOCs and APOE; found in blood and carries lipids from body tissues to the liver as part of the reverse cholesterol transport process. |
| | GO:0034363 | | intermediate-density lipoprotein particle | | A triglyceride-rich lipoprotein particle that typically contains APOB100, APOE and APOCs and has a density of 1.006-1.019 g/ml and a diameter of between 25-30 nm. IDL particles are found in blood and are formed by the delipidation of very-low-density lipoprotein particles (VLDL). IDL particles are removed from blood by the liver, following binding to the APOE receptor, or are converted to low-density lipoprotein (LDL). |
| | GO:0034362 | | low-density lipoprotein particle | | A lipoprotein particle, rich in cholesterol esters and low in triglycerides that is typically composed of APOB100 and APOE and has a density of 1.02-1.06 g/ml and a diameter of between 20-25 nm. LDL particles are formed from VLDL particles (via IDL) by the loss of triglyceride and gain of cholesterol ester. They transport endogenous cholesterol (and to some extent triglycerides) from peripheral tissues back to the liver. |
| | GO:0034366 | | spherical high-density lipoprotein particle | | A mature high-density lipoprotein (HDL) particle, converted from discoidal HDL particles following the esterification of cholesterol in the particle by phosphatidylcholine-sterol O-acyltransferase (lecithin cholesterol acyltransferase; LCAT). |
| | GO:0034361 | | very-low-density lipoprotein particle | | A triglyceride-rich lipoprotein particle that is typically composed of APOB100, APOE and APOCs and has a density of about 1.006 g/ml and a diameter of between 20-80 nm. It is found in blood and transports endogenous products (newly synthesized cholesterol and triglycerides) from the liver. |
Description
